Hikma Pharmaceuticals PLC (HIK) is a leading drug manufacturers-specialty and generic business based in the UK. It opened the day at 2238p after a previous close of 2241p. During the day the price has varied from a low of 2202p to a high of 2243p. The latest price was 2213p (25 minute delay). Hikma Pharmaceuticals is listed on the London Stock Exchange (LSE) and employs 8,600 staff. All prices are listed in pence sterling.
How to buy shares in Hikma Pharmaceuticals
- Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: HIK in this case.
- Research Hikma Pharmaceuticals shares. The platform should provide the latest information available.
- Buy your Hikma Pharmaceuticals shares. It's that simple.
Range of markets
What's in this guide?
- Can I buy shares in Hikma Pharmaceuticals?
- Has coronavirus impacted Hikma Pharmaceuticals shares?
- Hikma Pharmaceuticals shares summary
- Compare share dealing platforms
- Is Hikma Pharmaceuticals stock a buy or sell?
- Performance over time
- Is Hikma Pharmaceuticals suitable for ethical investing?
- Are Hikma Pharmaceuticals shares over-valued?
- How volatile are Hikma Pharmaceuticals shares?
- Does Hikma Pharmaceuticals pay a dividend?
- Have Hikma Pharmaceuticals shares ever split?
- Other common questions
How has coronavirus impacted Hikma Pharmaceuticals's share price?
Since the stock market crash that started in February 2020, Hikma Pharmaceuticals's share price has had significant positive movement.
Its last market close was 2018p, which is 4.48% up on its pre-crash value of 1927.5p and 26.44% up on the lowest point reached during the March 2020 crash when the shares fell as low as 1596p.
If you had bought £1,000 worth of Hikma Pharmaceuticals shares at the start of February 2020, those shares would have been worth £929.19 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £1,102.03.
Hikma Pharmaceuticals share price (LSE:HIK)Use our graph to track the performance of HIK stocks over time.
Hikma Pharmaceuticals shares at a glance
|52-week range||2044p - 2702.8119p|
|50-day moving average||2234.64p|
|200-day moving average||2407.525p|
|Wall St. target price||27.62p|
|Dividend yield||52p (1.83%)|
|Earnings per share (TTM)||146.9p|
Fees for buying 20x Hikma Pharmaceuticals shares with popular platforms
Share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
|Platform||Platform fee||Min. initial deposit||Trading fee estimate|
|Capital at risk|
|Capital at risk|
|Capital at risk|
|Capital at risk|
|£9.99 per month||No minimum||£7.99
|Capital at risk|
|Capital at risk|
|£36 per year||£20||£9.50
|Capital at risk|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Is it a good time to buy Hikma Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is Hikma Pharmaceuticals under- or over-valued?
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.
Hikma Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Hikma Pharmaceuticals shares trade at around 14x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Hikma Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.3791. A PEG ratio over 1 can be interpreted as meaning shares are overvalued at the current rate of growth, or may anticipate an acceleration in growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Hikma Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Hikma Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £726 million.
The EBITDA is a measure of a Hikma Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||£2.4 billion|
|Operating margin TTM||24.7%|
|Gross profit TTM||£1.2 billion|
|Return on assets TTM||9.19%|
|Return on equity TTM||22.17%|
|Market capitalisation||£4.8 billion|
TTM: trailing 12 months
Environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Hikma Pharmaceuticals.
Total ESG risk score
Hikma Pharmaceuticals's total ESG risk: 30.38
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Hikma Pharmaceuticals's overall score of 30.38 (as at 01/01/2019) is pretty weak – landing it in it in the 70th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Hikma Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Hikma Pharmaceuticals's environmental score: 0.84/100
Hikma Pharmaceuticals's social score: 19.63/100
Hikma Pharmaceuticals's governance score: 10.6/100
Hikma Pharmaceuticals's controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Hikma Pharmaceuticals scored a 1 out of 5 for controversy – the highest score possible, reflecting that Hikma Pharmaceuticals has managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||30.38|
|Total ESG percentile||69.56|
|Level of controversy||1|
Hikma Pharmaceuticals share dividends
Dividend yield: 1.83% of stock value
Forward annual dividend yield: 1.83% of stock value
Dividend payout ratio: 24.89% of net profits
Hikma Pharmaceuticals has recently paid out dividends equivalent to 1.83% of its share value annually.
Hikma Pharmaceuticals has paid out, on average, around 24.89% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.83% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 1.83% return on their shares, in the form of dividend payments. In Hikma Pharmaceuticals's case, that would currently equate to about 52p per share.
While Hikma Pharmaceuticals's payout ratio might seem low, this can signify that the company is investing more in its future growth.
The latest dividend was paid out to all shareholders who bought their shares by 19 August 2021 (the "ex-dividend date").
Have Hikma Pharmaceuticals's shares ever split?
Hikma Pharmaceuticals's shares were split on 4 September 2013.
Share price volatility
Over the last 12 months, Hikma Pharmaceuticals's shares have ranged in value from as little as 2044p up to 2702.8119p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Hikma Pharmaceuticals's is -0.112. This would suggest that Hikma Pharmaceuticals's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Hikma Pharmaceuticals has bucked the trend.
Shares similar to Hikma Pharmaceuticals
Hikma Pharmaceuticals in the news
Hikma Ventures leads Series A extension in NuvoAir to support its platform for patient-centric care and clinical trials
Hikma expands into Canada with acquisition of Teligent sterile injectable assets
Hikma Launches New 503B Sterile Compounding Business
Frequently asked questions
More guides on Finder
Shiba Inu (SHIB) price, history and performance
This guide explores the different ways of buying Shiba Inu on a cryptocurrency exchange as well as where you should store your cryptocurrency.
How to buy Telefónica (TEF) shares in the UK
Ever wondered how to buy shares in Telefónica? We explain how and compare a range of providers that can give you access to many brands, including Telefónica.
How to buy TSMC (TSM) shares in the UK
Ever wondered how to buy shares in TSMC? We explain how and compare a range of providers that can give you access to many brands, including Taiwan Semiconductor.
How to buy Mobileye shares when it goes public
Everything we know about the Mobileye IPO, plus information on how to buy shares.
How to buy Banco Bilbao Vizcaya Argentaria (BBVA) shares in the UK
Ever wondered how to buy shares in Banco Bilbao Vizcaya Argentaria? We explain how and compare a range of providers that can give you access to many brands, including BBVA.
How to buy Bone Biologics (BBLG) shares in the UK
Ever wondered how to buy shares in Bone Biologics? We explain how and compare a range of providers that can give you access to many brands, including Bone Biologics.
Dent (DENT) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy Dent, lists some exchanges where you can get it and provides daily price data on DENT.
How to buy The Sandbox (SAND) in the UK
This guide provides step-by-step instructions on how to buy The Sandbox, lists some exchanges where you can get it and provides daily price data on SAND.
Halifax Cashback Credit Card review 2022
With no annual fee, the Halifax Cashback Credit Card could be a good option for those looking to earn something back on their spending.
How to buy Polestar (PSNY) shares when it goes public
Everything we know about the Polestar IPO, plus information on how to buy shares.
Ask an Expert